Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma.

May CD, Landers SM, Bolshakov S, Ma X, Ingram DR, Kivlin CM, Watson KL, Sannaa GAA, Bhalla AD, Wang WL, Lazar AJ, Torres KE.

Cancer Biol Ther. 2017 Oct 3;18(10):816-826. doi: 10.1080/15384047.2017.1373230. Epub 2017 Nov 3.

2.

Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation.

de Graaff MA, Yu JS, Beird HC, Ingram DR, Nguyen T, Juehui Liu J, Bolshakov S, Szuhai K, Åman P, Torres KE, Lev D, Nielsen TO, Bovée JV, Lazar AJ, Somaiah N.

Lab Invest. 2016 Aug;96(8):885-94. doi: 10.1038/labinvest.2016.64. Epub 2016 Jun 6.

3.

Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor.

Kivlin CM, Watson KL, Al Sannaa GA, Belousov R, Ingram DR, Huang KL, May CD, Bolshakov S, Landers SM, Kalam AA, Slopis JM, McCutcheon IE, Pollock RE, Lev D, Lazar AJ, Torres KE.

Cancer Biol Ther. 2016;17(2):129-38. doi: 10.1080/15384047.2015.1108486. Epub 2015 Dec 9.

4.

AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas.

May CD, Garnett J, Ma X, Landers SM, Ingram DR, Demicco EG, Al Sannaa GA, Vu T, Han L, Zhang Y, Kivlin CM, Bolshakov S, Kalam AA, Liu J, Zhou F, Broccoli D, Wang WL, Lazar AJ, Pollock RE, Lev D, Torres KE.

BMC Cancer. 2015 Nov 14;15:901. doi: 10.1186/s12885-015-1916-3.

5.

SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.

Bill KL, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, Casadei L, Braggio D, Lopez G, Zewdu A, Bid H, Lev D, Pollock RE.

Clin Cancer Res. 2016 Mar 1;22(5):1150-60. doi: 10.1158/1078-0432.CCR-15-1522. Epub 2015 Oct 16.

6.

HDAC Inhibition for the Treatment of Epithelioid Sarcoma: Novel Cross Talk Between Epigenetic Components.

Lopez G, Song Y, Lam R, Ruder D, Creighton CJ, Bid HK, Bill KL, Bolshakov S, Zhang X, Lev D, Pollock RE.

Mol Cancer Res. 2016 Jan;14(1):35-43. doi: 10.1158/1541-7786.MCR-15-0295. Epub 2015 Sep 22.

7.

Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors.

Shang H, Braggio D, Lee YJ, Al Sannaa GA, Creighton CJ, Bolshakov S, Lazar AJ, Lev D, Pollock RE.

Cancer. 2015 Nov 15;121(22):4088-96. doi: 10.1002/cncr.29564. Epub 2015 Sep 8.

8.

The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma.

Bill KL, Garnett J, Ma X, May CD, Bolshakov S, Lazar AJ, Lev DC, Pollock RE.

Lab Invest. 2015 Aug;95(8):951-61. doi: 10.1038/labinvest.2015.62. Epub 2015 Jun 1.

9.

CXCR4/CXCL12 mediate autocrine cell- cycle progression in NF1-associated malignant peripheral nerve sheath tumors.

Mo W, Chen J, Patel A, Zhang L, Chau V, Li Y, Cho W, Lim K, Xu J, Lazar AJ, Creighton CJ, Bolshakov S, McKay RM, Lev D, Le LQ, Parada LF.

Cell. 2013 Feb 28;152(5):1077-90. doi: 10.1016/j.cell.2013.01.053. Epub 2013 Feb 21.

10.

MiR-155 is a liposarcoma oncogene that targets casein kinase-1α and enhances β-catenin signaling.

Zhang P, Bill K, Liu J, Young E, Peng T, Bolshakov S, Hoffman A, Song Y, Demicco EG, Terrada DL, Creighton CJ, Anderson ML, Lazar AJ, Calin GG, Pollock RE, Lev D.

Cancer Res. 2012 Apr 1;72(7):1751-62. doi: 10.1158/0008-5472.CAN-11-3027. Epub 2012 Feb 20.

11.

Involvement of the PI3K/Akt pathway in myxoid/round cell liposarcoma.

Demicco EG, Torres KE, Ghadimi MP, Colombo C, Bolshakov S, Hoffman A, Peng T, Bovée JV, Wang WL, Lev D, Lazar AJ.

Mod Pathol. 2012 Feb;25(2):212-21. doi: 10.1038/modpathol.2011.148. Epub 2011 Oct 21.

12.

'Difficult to diagnose' desmoid tumours: a potential role for CTNNB1 mutational analysis.

Colombo C, Bolshakov S, Hajibashi S, Lopez-Terrada L, Wang WL, Rao P, Benjamin RS, Lazar AJ, Lev D.

Histopathology. 2011 Aug;59(2):336-40. doi: 10.1111/j.1365-2559.2011.03932.x.

PMID:
21884214
13.

Increased midkine expression correlates with desmoid tumour recurrence: a potential biomarker and therapeutic target.

Colombo C, Creighton CJ, Ghadimi MP, Bolshakov S, Warneke CL, Zhang Y, Lusby K, Zhu S, Lazar AJ, West RB, van de Rijn M, Lev D.

J Pathol. 2011 Dec;225(4):574-82. doi: 10.1002/path.2951. Epub 2011 Aug 8.

PMID:
21826666
14.

Pleomorphic liposarcoma: clinical observations and molecular variables.

Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, Colombo C, Hoffman A, Broccoli D, Hornick JL, Lazar AJ, Pisters P, Pollock RE, Lev D.

Cancer. 2011 Dec 1;117(23):5359-69. doi: 10.1002/cncr.26195. Epub 2011 May 19.

15.

Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.

Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, Belousov R, Wang S, Lahat G, Liu J, Hernandez B, Lazar AJ, Lev D.

Clin Cancer Res. 2011 Jun 15;17(12):3943-55. doi: 10.1158/1078-0432.CCR-11-0193. Epub 2011 May 3.

16.

Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model.

Sakharpe A, Lahat G, Gulamhusein T, Liu P, Bolshakov S, Nguyen T, Zhang P, Belousov R, Young E, Xie X, Rao P, Hornick JL, Lazar AJ, Pollock RE, Lev D.

Oncologist. 2011;16(4):512-22. doi: 10.1634/theoncologist.2010-0174. Epub 2011 Feb 28.

17.

Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.

Lopez G, Torres K, Liu J, Hernandez B, Young E, Belousov R, Bolshakov S, Lazar AJ, Slopis JM, McCutcheon IE, McConkey D, Lev D.

Cancer Res. 2011 Jan 1;71(1):185-96. doi: 10.1158/0008-5472.CAN-10-2799. Epub 2010 Nov 16. Erratum in: Cancer Res. 2015 Apr 15;75(8):1771-4.

18.

An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.

Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, López-Terrada DH, Oliveira AM, Lazar AJ, Lev D.

Lab Invest. 2011 Mar;91(3):392-403. doi: 10.1038/labinvest.2010.185. Epub 2010 Nov 8.

19.

Vimentin is a novel AKT1 target mediating motility and invasion.

Zhu QS, Rosenblatt K, Huang KL, Lahat G, Brobey R, Bolshakov S, Nguyen T, Ding Z, Belousov R, Bill K, Luo X, Lazar A, Dicker A, Mills GB, Hung MC, Lev D.

Oncogene. 2011 Jan 27;30(4):457-70. doi: 10.1038/onc.2010.421. Epub 2010 Sep 20.

20.

Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies.

Lahat G, Zhu QS, Huang KL, Wang S, Bolshakov S, Liu J, Torres K, Langley RR, Lazar AJ, Hung MC, Lev D.

PLoS One. 2010 Apr 16;5(4):e10105. doi: 10.1371/journal.pone.0010105.

21.

Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors.

Lazar AJ, Tuvin D, Hajibashi S, Habeeb S, Bolshakov S, Mayordomo-Aranda E, Warneke CL, Lopez-Terrada D, Pollock RE, Lev D.

Am J Pathol. 2008 Nov;173(5):1518-27. doi: 10.2353/ajpath.2008.080475. Epub 2008 Oct 2.

22.

Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.

Ren W, Korchin B, Lahat G, Wei C, Bolshakov S, Nguyen T, Merritt W, Dicker A, Lazar A, Sood A, Pollock RE, Lev D.

Clin Cancer Res. 2008 Sep 1;14(17):5466-75. doi: 10.1158/1078-0432.CCR-08-0562.

23.

Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation.

Hannay JA, Liu J, Zhu QS, Bolshakov SV, Li L, Pisters PW, Lazar AJ, Yu D, Pollock RE, Lev D.

Mol Cancer Ther. 2007 May;6(5):1650-60.

24.

Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis.

Liu J, Zhan M, Hannay JA, Das P, Bolshakov SV, Kotilingam D, Yu D, Lazar AF, Pollock RE, Lev D.

Mol Cancer Res. 2006 Nov;4(11):803-10. Epub 2006 Oct 31.

25.

A concise synthesis of ginkgolide M, a minor component of a terpene trilactone fraction from ginkgo biloba roots.

Bolshakov S, Dzyuba SV, Decatur J, Nakanishi K.

J Nat Prod. 2006 Mar;69(3):429-31.

PMID:
16562852
26.

Efficient asymmetric synthesis of (+)-SCH 351448.

Bolshakov S, Leighton JL.

Org Lett. 2005 Aug 18;7(17):3809-12.

27.

Genomic alterations in spontaneous and carcinogen-induced murine melanoma cell lines.

Melnikova VO, Bolshakov SV, Walker C, Ananthaswamy HN.

Oncogene. 2004 Mar 25;23(13):2347-56.

PMID:
14743208
28.

Mutant p53 is constitutively phosphorylated at Serine 15 in UV-induced mouse skin tumors: involvement of ERK1/2 MAP kinase.

Melnikova VO, Santamaria AB, Bolshakov SV, Ananthaswamy HN.

Oncogene. 2003 Sep 4;22(38):5958-66.

PMID:
12955074
29.

p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas.

Bolshakov S, Walker CM, Strom SS, Selvan MS, Clayman GL, El-Naggar A, Lippman SM, Kripke ML, Ananthaswamy HN.

Clin Cancer Res. 2003 Jan;9(1):228-34.

30.
31.

Mapping and identification of essential gene functions on the X chromosome of Drosophila.

Peter A, Schöttler P, Werner M, Beinert N, Dowe G, Burkert P, Mourkioti F, Dentzer L, He Y, Deak P, Benos PV, Gatt MK, Murphy L, Harris D, Barrell B, Ferraz C, Vidal S, Brun C, Demaille J, Cadieu E, Dreano S, Gloux S, Lelaure V, Mottier S, Galibert F, Borkova D, Miñana B, Kafatos FC, Bolshakov S, Sidén-Kiamos I, Papagiannakis G, Spanos L, Louis C, Madueño E, de Pablos B, Modolell J, Bucheton A, Callister D, Campbell L, Henderson NS, McMillan PJ, Salles C, Tait E, Valenti P, Saunders RD, Billaud A, Pachter L, Klapper R, Janning W, Glover DM, Ashburner M, Bellen HJ, Jäckle H, Schäfer U.

EMBO Rep. 2002 Jan;3(1):34-8. Epub 2001 Dec 19.

32.

UV irradiation augments lymphoid malignancies in mice with one functional copy of wild-type p53.

Jiang W, Ananthaswamy HN, Muller HK, Ouhtit A, Bolshakov S, Ullrich SE, El-Naggar AK, Kripke ML.

Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9790-5. Epub 2001 Jul 31.

33.

From first base: the sequence of the tip of the X chromosome of Drosophila melanogaster, a comparison of two sequencing strategies.

Benos PV, Gatt MK, Murphy L, Harris D, Barrell B, Ferraz C, Vidal S, Brun C, Demaille J, Cadieu E, Dreano S, Gloux S, Lelaure V, Mottier S, Galibert F, Borkova D, Miñana B, Kafatos FC, Bolshakov S, Sidén-Kiamos I, Papagiannakis G, Spanos L, Louis C, Madueño E, de Pablos B, Modolell J, Peter A, Schöttler P, Werner M, Mourkioti F, Beinert N, Dowe G, Schäfer U, Jäckle H, Bucheton A, Callister D, Campbell L, Henderson NS, McMillan PJ, Salles C, Tait E, Valenti P, Saunders RD, Billaud A, Pachter L, Glover DM, Ashburner M.

Genome Res. 2001 May;11(5):710-30.

34.

The genome sequence of Drosophila melanogaster.

Adams MD, Celniker SE, Holt RA, Evans CA, Gocayne JD, Amanatides PG, Scherer SE, Li PW, Hoskins RA, Galle RF, George RA, Lewis SE, Richards S, Ashburner M, Henderson SN, Sutton GG, Wortman JR, Yandell MD, Zhang Q, Chen LX, Brandon RC, Rogers YH, Blazej RG, Champe M, Pfeiffer BD, Wan KH, Doyle C, Baxter EG, Helt G, Nelson CR, Gabor GL, Abril JF, Agbayani A, An HJ, Andrews-Pfannkoch C, Baldwin D, Ballew RM, Basu A, Baxendale J, Bayraktaroglu L, Beasley EM, Beeson KY, Benos PV, Berman BP, Bhandari D, Bolshakov S, Borkova D, Botchan MR, Bouck J, Brokstein P, Brottier P, Burtis KC, Busam DA, Butler H, Cadieu E, Center A, Chandra I, Cherry JM, Cawley S, Dahlke C, Davenport LB, Davies P, de Pablos B, Delcher A, Deng Z, Mays AD, Dew I, Dietz SM, Dodson K, Doup LE, Downes M, Dugan-Rocha S, Dunkov BC, Dunn P, Durbin KJ, Evangelista CC, Ferraz C, Ferriera S, Fleischmann W, Fosler C, Gabrielian AE, Garg NS, Gelbart WM, Glasser K, Glodek A, Gong F, Gorrell JH, Gu Z, Guan P, Harris M, Harris NL, Harvey D, Heiman TJ, Hernandez JR, Houck J, Hostin D, Houston KA, Howland TJ, Wei MH, Ibegwam C, Jalali M, Kalush F, Karpen GH, Ke Z, Kennison JA, Ketchum KA, Kimmel BE, Kodira CD, Kraft C, Kravitz S, Kulp D, Lai Z, Lasko P, Lei Y, Levitsky AA, Li J, Li Z, Liang Y, Lin X, Liu X, Mattei B, McIntosh TC, McLeod MP, McPherson D, Merkulov G, Milshina NV, Mobarry C, Morris J, Moshrefi A, Mount SM, Moy M, Murphy B, Murphy L, Muzny DM, Nelson DL, Nelson DR, Nelson KA, Nixon K, Nusskern DR, Pacleb JM, Palazzolo M, Pittman GS, Pan S, Pollard J, Puri V, Reese MG, Reinert K, Remington K, Saunders RD, Scheeler F, Shen H, Shue BC, Sidén-Kiamos I, Simpson M, Skupski MP, Smith T, Spier E, Spradling AC, Stapleton M, Strong R, Sun E, Svirskas R, Tector C, Turner R, Venter E, Wang AH, Wang X, Wang ZY, Wassarman DA, Weinstock GM, Weissenbach J, Williams SM, WoodageT, Worley KC, Wu D, Yang S, Yao QA, Ye J, Yeh RF, Zaveri JS, Zhan M, Zhang G, Zhao Q, Zheng L, Zheng XH, Zhong FN, Zhong W, Zhou X, Zhu S, Zhu X, Smith HO, Gibbs RA, Myers EW, Rubin GM, Venter JC.

Science. 2000 Mar 24;287(5461):2185-95.

PMID:
10731132
35.

From sequence to chromosome: the tip of the X chromosome of D. melanogaster.

Benos PV, Gatt MK, Ashburner M, Murphy L, Harris D, Barrell B, Ferraz C, Vidal S, Brun C, Demailles J, Cadieu E, Dreano S, Gloux S, Lelaure V, Mottier S, Galibert F, Borkova D, Minana B, Kafatos FC, Louis C, Sidén-Kiamos I, Bolshakov S, Papagiannakis G, Spanos L, Cox S, Madueño E, de Pablos B, Modolell J, Peter A, Schöttler P, Werner M, Mourkioti F, Beinert N, Dowe G, Schäfer U, Jäckle H, Bucheton A, Callister DM, Campbell LA, Darlamitsou A, Henderson NS, McMillan PJ, Salles C, Tait EA, Valenti P, Saunder RD, Glover DM.

Science. 2000 Mar 24;287(5461):2220-2.

PMID:
10731137
36.
37.

Detection of mutations and polymorphisms in the p53 tumor suppressor gene by single-strand conformation polymorphism analysis.

Kutach LS, Bolshakov S, Ananthaswamy HN.

Electrophoresis. 1999 Jun;20(6):1204-10. Review.

PMID:
10380760

Supplemental Content

Loading ...
Support Center